Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

R3530

Sigma-Aldrich

Rifabutin

>98% (HPLC), powder, antibiotic

Sinônimo(s):

Ansamycin, Ansatipine (Farmitalia), LM-427, Mycobutin (Farmitalia)

Faça loginpara ver os preços organizacionais e de contrato


About This Item

Fórmula empírica (Notação de Hill):
C46H62N4O11
Número CAS:
Peso molecular:
847.00
Código UNSPSC:
12352200
NACRES:
NA.77

Nome do produto

Rifabutin, >98% (HPLC), powder

Nível de qualidade

Ensaio

>98% (HPLC)

Formulário

powder

condição de armazenamento

protect from light

solubilidade

DMSO: >5 mg/mL

espectro de atividade do antibiótico

neoplastics

Modo de ação

enzyme | inhibits

originador

Johnson & Johnson

Condições de expedição

wet ice

temperatura de armazenamento

−20°C

cadeia de caracteres SMILES

[N+H]1(CCC2(NC3=C4NC(=O)\C(=C/C=C/[C@@H]([C@@H]([C@H]([C@H]([C@H]([C@@H]([C@@H]([C@H](\C=C\O[C@]5(Oc6c(c(c(c(c6C)[O-])C4=O)C3=N2)C5=O)C)OC)C)OC(=O)C)C)O)C)O)C)\C)CC1)CC(C)C

InChI

1S/C46H62N4O11/c1-22(2)21-50-18-16-46(17-19-50)48-34-31-32-39(54)28(8)42-33(31)43(56)45(10,61-42)59-20-15-30(58-11)25(5)41(60-29(9)51)27(7)38(53)26(6)37(52)23(3)13-12-14-24(4)44(57)47-36(40(32)55)35(34)49-46/h12-15,20,22-23,25-27,30,37-38,41,49,52-54H,16-19,21H2,1-11H3,(H,47,57)/b13-12+,20-15+,24-14-/t23-,25+,26+,27+,30-,37-,38+,41+,45-/m0/s1

chave InChI

ATEBXHFBFRCZMA-VXTBVIBXSA-N

Procurando produtos similares? Visita Guia de comparação de produtos

Ações bioquímicas/fisiológicas

Rifabutin is an antibiotic; antitumor.
Rifabutin is an antibiotic; antitumor. Rifabutin interferes with HSP-90 molecular chaperone, enhances ubiquitination and protein degradation, and inactivates bacterial RNA polymerase.

Características e benefícios

This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Equipamento de proteção individual

Eyeshields, Gloves, type N95 (US)


Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

Não está vendo a versão correta?

Se precisar de uma versão específica, você pode procurar um certificado específico pelo número do lote ou da remessa.

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Os clientes também visualizaram

C Y Tay et al.
Alimentary pharmacology & therapeutics, 36(11-12), 1076-1083 (2012-10-18)
Helicobacter pylori eradication rates with standard triple therapy are declining worldwide. The optimal management of H. pylori is evolving and new treatment combinations for antibiotic resistant H. pylori strains are required, especially for patients with penicillin allergy. To review the
Jakko van Ingen et al.
American journal of respiratory and critical care medicine, 186(6), 559-565 (2012-06-30)
Currently recommended multidrug treatment regimens for Mycobacterium avium complex (MAC) lung disease yield limited cure rates. This results, in part, from incomplete understanding of the pharmacokinetics and pharmacodynamics of the drugs. To study pharmacokinetics, pharmacodynamics, and drug interactions of multidrug
Matthew D Hickey et al.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 19(4), 457-461 (2013-03-26)
Latent tuberculosis infection is an important problem for solid organ transplant recipients because of the frequency of its occurrence and its potential for reactivation. Because of the high mortality rate associated with active tuberculosis infections in transplant recipients, guidelines from
J P Gisbert et al.
Alimentary pharmacology & therapeutics, 35(8), 941-947 (2012-03-01)
In some cases, Helicobacter pylori infection persists even after three eradication treatments. To evaluate the efficacy of an empirical fourth-line rescue regimen with rifabutin in patients with three eradication failures. Multicentre, prospective study. In whom the following three treatments had
Kelly E Dooley et al.
Journal of acquired immune deficiency syndromes (1999), 62(1), 21-27 (2012-10-19)
Cotreatment of tuberculosis (TB) and HIV among coinfected patients is now the standard of care. Rifampin (RIF) is a standard part of TB treatment but is a potent inducer of drug metabolizing enzymes. This study evaluated the effect of RIF

Artigos

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica